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background:  Intra-aortic balloon pump (IABP) therapy results in afterload reduction and an increase in diastolic coronary flow. 
Controversy exists regarding its benefit in cardiogenic shock complicating ST-elevation myocardial infarction (STEMI).
methods:  We analysed 734 patients with STEMI and cardiogenic shock undergoing PPCI between 2004-2011 at 8 tertiary cardiac centres 
in London, UK. The primary outcome was all-cause mortality at 3 years. We used multivariate Cox proportional hazards regression; 
propensity-based matching; and inverse probability weighted (IPTW) analyses.
Results:  A total of 331 patients (45%) received IABP therapy. Those receiving IABP were more likely to have longer call-to-balloon 
times; previous history of revascularization; severe LV impairment; and undergo LMS/LAD intervention and multi-vessel intervention. The 
unadjusted 3-year mortality rates were greater in those receiving IABP therapy (52.0% vs. 32.5%, p<0.001). Multivariate analysis indicated 
that IABP use was an independent predictor for mortality at 3 years (HR=1.45, 95% CI:1.08-1.94, p=0.015). When adjusting for measured 
confounders, this association was no longer seen, both in propensity-matched analyses (HR=1.24, 95% CI:0.86-1.78, p=0.256) and in 
IPTW analyses (HR=1.27, 95% CI:0.95-1.70, p=0.105).
conclusion:  In this observational analysis of patients with STEMI and cardiogenic shock, when adjusting for measured confounders, IABP 
therapy was not associated with long-term survival benefit.
 
